Results 211 to 220 of about 85,963 (263)
Some of the next articles are maybe not open access.
Current Medicinal Chemistry, 2019
Janus kinases (JAKs) are a family of non-receptor tyrosine kinases, composed by four members, JAK1, JAK2, JAK3 and TYK2. JAKs are involved in different inflammatory and autoimmune diseases, as well as in malignancies, through the activation of the JAK/STAT signalling pathway.
Musumeci, Francesca +7 more
openaire +3 more sources
Janus kinases (JAKs) are a family of non-receptor tyrosine kinases, composed by four members, JAK1, JAK2, JAK3 and TYK2. JAKs are involved in different inflammatory and autoimmune diseases, as well as in malignancies, through the activation of the JAK/STAT signalling pathway.
Musumeci, Francesca +7 more
openaire +3 more sources
Future Medicinal Chemistry, 2014
Consisting of four members, JAK1, JAK2, JAK3 and TYK2, the JAK kinases have emerged as important targets for proliferative and immune-inflammatory disorders. Recent progress in the discovery of selective inhibitors has been significant, with selective compounds now reported for each isoform.
Brian W, Dymock +3 more
openaire +2 more sources
Consisting of four members, JAK1, JAK2, JAK3 and TYK2, the JAK kinases have emerged as important targets for proliferative and immune-inflammatory disorders. Recent progress in the discovery of selective inhibitors has been significant, with selective compounds now reported for each isoform.
Brian W, Dymock +3 more
openaire +2 more sources
JAK inhibitors for rheumatoid arthritis
Expert Opinion on Investigational Drugs, 2023JAK (Janus kinase) is a type of non-receptor tyrosine kinase that includes JAK1, JAK2, JAK3, and Tyk2. Currently, there are five JAK inhibitors approved for treating rheumatoid arthritis. These inhibitors vary in their selectivity for different JAK isoforms.This review outlines the mode of actions and the results of Phase III trials of the JAK ...
Satoshi Kubo +2 more
openaire +2 more sources
JAK inhibitors and black box warnings: what is the future for JAK inhibitors?
Expert Review of Clinical Immunology, 2023Janus kinase inhibitors (JAKi) have dramatically improved the treatment of various autoimmune and myeloproliferative disorders. Recently, concern has arisen regarding their safety in patients with rheumatoid arthritis.Here, we provide a comprehensive summary of the major current and emerging JAKi and their indications, address recent studies on ...
Kate Tokareva +7 more
openaire +2 more sources
Case report: JAK inhibitor treatment of immune dysregulation symptoms in a patient with PTPN2 deficiency [PDF]
Frontiers in ImmunologyKaraulov Alexander, Raykina Elena
exaly +2 more sources
JAK inhibitors for the treatment of vitiligo
Journal of Dermatological ScienceVitiligo is an autoimmune disease involving melanocyte-targeting T cells initiated by environmental and genetic factors. Steroids and tacrolimus have been used as topical treatments. Recently, novel topical agents targeting Janus kinase (JAK), a family of tyrosine kinases that regulates cytokine signaling, have emerged.
Shintaro, Inoue +3 more
openaire +2 more sources
JAK Inhibitor in CALR-Mutant Myelofibrosis
New England Journal of Medicine, 2014na
PASSAMONTI, FRANCESCO +2 more
openaire +6 more sources
Nihon rinsho. Japanese journal of clinical medicine, 2013
Biologics targeting inflammatory cytokine has become a standardized tool for remission induction in rheumatoid arthritis (RA). However, it is handled under restricted conditions and their cost of acquisition is high. Small molecule drugs targeting Janus kinase (JAK), a molecule involved in intracellular signaling pathway has shown similar treatment ...
Kunihiro, Yamaoka, Yoshiya, Tanaka
openaire +1 more source
Biologics targeting inflammatory cytokine has become a standardized tool for remission induction in rheumatoid arthritis (RA). However, it is handled under restricted conditions and their cost of acquisition is high. Small molecule drugs targeting Janus kinase (JAK), a molecule involved in intracellular signaling pathway has shown similar treatment ...
Kunihiro, Yamaoka, Yoshiya, Tanaka
openaire +1 more source
Drug News & Perspectives, 2005
In humans, the Janus protein tyrosine kinase family (JAKs) contains four members: JAK1, JAK2, JAK3 and TYK2. JAKs phosphorylate signal transducers and activators of transcription (STATs) simultaneously with other phosphorylations required for activation, and there are several cellular mechanisms in place to inhibit JAK/STAT signaling. That one might be
openaire +2 more sources
In humans, the Janus protein tyrosine kinase family (JAKs) contains four members: JAK1, JAK2, JAK3 and TYK2. JAKs phosphorylate signal transducers and activators of transcription (STATs) simultaneously with other phosphorylations required for activation, and there are several cellular mechanisms in place to inhibit JAK/STAT signaling. That one might be
openaire +2 more sources
Successful Treatment of Granulomatous Rosacea by JAK Inhibitor Abrocitinib: A Case Report
Clinical, Cosmetic and Investigational Dermatology, 2023Yang Ding, Xianhong Yang, Yan Teng
exaly